Daily Trades

My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.
When I see that the stock is selling for just $1.19 per share - and billionaire investors Steve Cohen and Jim Simons own 3.5 million shares, count me interested.
Pharmaceutical company Esperion Therapeutics (SYM: ESPR) develops and commercializes medicines for the treatment of patients with elevated lowdensity lipoprotein cholesterol, or LDL – the “bad” cholesterol, which makes up a good deal of your body’s total cholesterol.
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it. 
At around $5 per share, I think Esperion Therapeutics (SYM: ESPR), will go down as one of the best biotech buys you’ve ever made.

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Categories

Recent posts

Tags

Connect with Us

My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
For our December issue, I’m adding a stock to our weight-loss trade: Altimmune (SYM: ALT) here at $3.75.
When I see that the stock is selling for just $1.19 per share - and billionaire investors Steve Cohen and Jim Simons own 3.5 million shares, count me interested.
Pharmaceutical company Esperion Therapeutics (SYM: ESPR) develops and commercializes medicines for the treatment of patients with elevated lowdensity lipoprotein cholesterol, or LDL – the “bad” cholesterol, which makes up a good deal of your body’s total cholesterol.
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it. 
At around $5 per share, I think Esperion Therapeutics (SYM: ESPR), will go down as one of the best biotech buys you’ve ever made.

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.